Sera: 3 Key Takeaways for Long-Term Investors
Key PointsTest volume increased approximately fivefold from the first quarter of 2026.
Three key takeaways emerge from Sera's (SERA -3.48%) third-quarter 2026 earnings conference call. First, test volume for PreTRM, the company's blood test predicting preterm birth risk, surged approximately fivefold from the first quarter of 2026. This growth is driven by expanding state Medicaid coverage and physician adoption of the diagnostic test.
Second, Medicaid's role as the primary catalyst for diagnostic adoption is crucial. In the U.S., state Medicaid programs cover roughly 40% to 43% of all births, making government policy the key driver behind broader diagnostic usage. Sera's largest reimbursed market opportunity to date is Florida, which boasts nearly 90,000 Medicaid births and around 4 million Medicaid lives.
Third, converting regulatory mandates into high-volume, reimbursed patient volume is a process that can take 12 months to 18 months. Clinicians need time to transition from initial trial usage to making the novel diagnostic test a standard component of prenatal care. This includes active field education, electronic record integrations, and clinician adoption, as seen with PreTRM.
Additionally, securing private insurance coverage requires demonstrating real-world utility and cost savings beyond government programs, which Sera is pursuing through active pilot programs with major national health plans and managed care organizations.
Written by urgent.news from Motley Fool's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
This story
This is one outlet's version. Read the fullest account.